Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40WGA | ISIN: GB00BQVXM815 | Ticker-Symbol: 5HU0
Frankfurt
06.06.25 | 21:38
2,020 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOGENYX PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
HEMOGENYX PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
2,0202,26006.06.

Aktuelle News zur HEMOGENYX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTRADING UPDATES: Valereum invests in Blubird; Hemogenyx raises funds3
DiHemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing189THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
► Artikel lesen
DiHemogenyx Pharma Plc - Placing to Raise £451,250 and Director's Dealing1
HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiHemogenyx Pharmaceuticals PLC - Second Patient Passes Initial Safety Tests127Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / June 3, 2025 / Hemogenyx Pharmaceuticals plc is pleased to...
► Artikel lesen
DiHemogenyx Pharma Plc - Second Patient Passes Initial Safety Tests1
30.05.Hemogenyx Pharma Plc - Total Voting Rights-
29.05.Hemogenyx Pharma Plc - Result of AGM-
14.05.Hemogenyx erweitert AML-Studie auf pädiatrische Patienten3
14.05.Hemogenyx expands AML trial to include pediatric patients2
14.05.Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol162Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML LONDON, UNITED KINGDOM / ACCESS Newswire / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to...
► Artikel lesen
14.05.Hemogenyx Pharma Plc - Pediatric Amendment to Clinical Protocol1
13.05.Hemogenyx Pharma Plc - AGM Correction-
08.05.Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing137THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
► Artikel lesen
08.05.Hemogenyx Pharma Plc - Placing to Raise £451,250 and Director's Dealing2
02.05.TRADING UPDATES: GlobalData suspends buyback; Hemogenyx trial progress2
02.05.Hemogenyx Pharma Plc - Notice of AGM-
02.05.Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy240LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase...
► Artikel lesen
02.05.Hemogenyx Pharma Plc - Second Patient Treated with HG-CT-1 CAR-T Therapy1
28.04.Hemogenyx Pharmaceuticals reports FY results4
28.04.Hemogenyx Pharmaceuticals PLC Announces Final Results35LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces...
► Artikel lesen
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1